Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Setubal – page 21

664 clinical trials in Setubal, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Setubal at a glance
664
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

664 trials in Setubal

Open in trial search

Cardiac failure

Not yet recruiting

Efficacy and Safety of Fixed‑Dose Combination of Dapagliflozin, Bisoprolol Fumarate, and Eplerenone vs Usual Care in Hospitalized Acute Heart Failure Patients

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol Fumarate
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Partial seizures

Not yet recruiting

Phase 3 Randomized Study of RAP-219 to Reduce Seizure Frequency in Adults with Focal Epilepsy

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:Rapport Therapeutics Inc.

Cardiovascular disorder+2

Not yet recruiting

Phase III Study Evaluating Efficacy and Safety of Petrelintide in Participants with Overweight or Obesity and Established Cardiovascular Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Pruritus

Not yet recruiting

Efficacy and safety of remibrutinib, pimecrolimus and tacrolimus in adults with severe chronic pruritus of unknown origin (CPUO): a randomized, placebo‑controlled trial

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pimecrolimus
  • Sponsor:Novartis Pharma AG

Bronchiectasis

Not yet recruiting

Efficacy and safety of galvokimig in adults with non‑cystic fibrosis bronchiectasis: a randomized, double‑blind, placebo‑controlled phase 2 trial

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Galvokimig
  • Sponsor:UCB Biopharma

Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Phase 2 Study of Inhaled AGMB-447 and Salbutamol Sulfate in Adults with Idiopathic Pulmonary Fibrosis to Evaluate Lung Function, Safety and Tolerability

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:Agomab Spain S.L.

Conjunctivitis allergic+1

Not yet recruiting

Efficacy and safety of Depigoid Olea 1000 DPP/ml compared with placebo in patients with moderate to severe allergic rhinoconjunctivitis due to olive pollen

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:LETI Pharma S.L.U.

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colorectal adenocarcinoma

Not yet recruiting

Phase 2 Study of ro7589831 with Pembrolizumab vs Pembrolizumab Alone in Adults with Advanced Colorectal Cancer (MSI‑High or dMMR)

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vividion Therapeutics Inc.

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Setubal

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking studies focusing on cardiovascular disease prevention and treatment, including innovative approaches to reduce major cardiovascular events and stroke prevention in patients with atrial fibrillation.

  • Lipoprotein management studies
  • Stroke prevention therapies
  • Atherosclerotic disease prevention

Research aims to evaluate new therapeutic options for reducing cardiovascular risks and improving patient outcomes.

02 Neurological Disorders

Clinical investigations targeting migraine management, including specialized studies for menstrual migraine prevention and acute treatment approaches.

  • Preventive migraine treatments
  • Acute migraine interventions
  • Gender-specific migraine studies

These trials explore innovative therapeutic solutions for various types of migraines.

03 Oncology Research

Advanced studies in breast cancer and non-small cell lung cancer treatments, focusing on targeted therapies and innovative treatment combinations.

  • Hormone receptor-positive breast cancer
  • Metastatic cancer treatments
  • Immunotherapy combinations

Research focuses on developing more effective treatments for various cancer types.

04 Autoimmune Conditions

Comprehensive research into systemic lupus erythematosus and related conditions, including specialized studies for lupus nephritis.

  • Lupus treatments
  • Kidney disease management
  • Chronic urticaria studies

Trials aim to improve treatment options for patients with autoimmune disorders.

05 Metabolic Disorders

Innovative research on type 2 diabetes complications, particularly focusing on diabetic retinopathy and its progression.

  • Diabetic eye disease
  • Glycemic control studies
  • Long-term disease management

Studies evaluate new approaches to managing diabetes-related complications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.